Study reviews the advancements in pharmacological treatments for neuropsychiatric syndromes in neurodegenerative disorders, discussing the complexities of managing symptoms such as depression, disinhibition, apathy, psychosis, and agitation to improve patient care.
Ascendis Pharma’s hypoparathyroidism drug scores European approval after refiling in the US
Ascendis Pharma’s Yorvipath was approved in Europe on Monday, days after the company refiled its application for the hypoparathyroidism hopeful in the US. Yorvipath, also
November 21, 2023